Journal of Clinical Immunology Publishes Octapharma USA Research on cutaquig® Evaluating PI Treatment Options (IMAGE)
Caption
An Octapharma-sponsored study published recently in The Journal of Clinical Immunology concludes that cutaquig® (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution) infusions at higher infusion rates, volume and therapy intervals met study endpoints for efficacy and safety, and were generally well tolerated with reduced infusion time, fewer infusion sites, and reduced frequency. The journal further reported the majority of study patients found the new investigational infusion regimens to be better or somewhat better than their previous regimens.
Credit
Octapharma USA
Usage Restrictions
N/A
License
Original content